Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Palbociclib

The first CDK4/6 inhibitor approved, in 2015, for hormone receptor-positive breast cancer. It blocks the cycle by which tumour cells divide. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?The molecule had already been synthesised in the early 2000s and sat on the shelf for years, before new studies revealed its potential.

PalbociclibGo to the active ingredient →
PalbociclibActive ingredientPalbociclibCat. No. P-P004-001CAS 571190-30-2
Palbociclib-d8Isotopically labelledPalbociclib-d8Cat. No. P-P004-003CAS 1628752-83-9

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.